Free Trial

Asensus Surgical Q2 2024 Earnings Report

Asensus Surgical logo
$0.35 0.00 (0.00%)
As of 08/22/2024

Asensus Surgical EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.05
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Asensus Surgical Revenue Results

Actual Revenue
$2.21 million
Expected Revenue
$1.30 million
Beat/Miss
Beat by +$910.00 thousand
YoY Revenue Growth
N/A

Asensus Surgical Announcement Details

Quarter
Q2 2024
Time
N/A

Asensus Surgical Earnings Headlines

The FED is losing the war on inflation
It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…
See More Asensus Surgical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Asensus Surgical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Asensus Surgical and other key companies, straight to your email.

About Asensus Surgical

Asensus Surgical (NYSEAMERICAN:ASXC), a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery (MIS) in the United States, Europe, the Middle East, Africa, and Asia. It digitizes the interface between the surgeon and the patient to perform performance-guided surgery for surgeons to deliver outcomes to patients. The company's products include Senhance System, a multi-port robotic surgery system that allows up to four arms to control robotic instruments and a camera for laparoscopic procedures; instruments and other products, including 3mm diameter instruments, 3mm and 5mm hooks, and articulating instruments; and Senhance ultrasonic system, an advanced energy device to deliver controlled energy to ligate and divide tissue. The company was formerly known as TransEnterix, Inc. and changed its name to Asensus Surgical, Inc. in February 2021. Asensus Surgical, Inc. is headquartered in Durham, North Carolina.

View Asensus Surgical Profile

More Earnings Resources from MarketBeat